Original articleClinical relevance of radionuclide angiography and antimyosin immunoscintigraphy for risk assessment in epirubicin cardiotoxicity
References (33)
4′-epi-doxorubicin, a new analogue of doxorubicin: a preliminary overview of preclinical and clinical data
Cancer Treat Rev
(1983)- et al.
Clinical and morphological cardiac findings after anthracyclines chemotherapy: analysis of 64 patients studied at necropsy
Am J Cardiol
(1983) - et al.
Cardiac and pulmonary toxicity
- et al.
The anthracyclines antineoplastic drugs
N Engl J Med
(1981) - et al.
Doxorubicin and epirubicin cardiotoxicity: experimental and clinical aspects
Adv Clin Oncol
(1988) - et al.
A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer
J Clin Oncol
(1985) - et al.
Epirubicin: a review of the pharmacology, clinical activity and adverse effects of an adriamicin analogue
J Clin Oncol
(1986) - et al.
Cardiac morphologic and functional changes induced by epirubicin chemotherapy
J Clin Oncol
(1989) - et al.
Anthracycline-induced cardiotoxicity and its relevance in cancer treatment
- et al.
Epirubicin cardiotoxicity: a study of 135 patients with advanced breast cancer
J Clin Oncol
(1990)
Phase II trial of epirubicin in advanced squamous, adeno- and large cell carcinoma of the lung
Eur J Cancer Clin Oncol
Epirubicin: a therapeutically active doxorubicin analogue with reduced cardiotoxicity
Dose response evaluation of adriamycin in human neoplasia
Cancer
Epirubicin at four different dose levels in metastatic breast cancer: a randomized trial
A phase I-II study of intensive dose adriamycin for advanced breast cancer
J Clin Oncol
Cyvadic in advanced soft tissue sarcoma: a randomized study comparing two schedules
Cited by (26)
Transduction catalysis: Doxorubicin amplifies rAAV-mediated gene expression in the cortex of higher-order vertebrates
2021, iScienceCitation Excerpt :As a chemotherapeutic drug, doxorubicin takes effect in cancer treatment by inhibiting cell proliferation and inducing apoptosis (Tacar et al., 2013). For non-dividing cells, such as neurons, there is less expectation of significant cytotoxicity (although cardiac tissues are known to be affected in high-dose schedules) (Maini et al., 1997). Direct delivery into the brain, rather than intravenous administration, restricts doxorubicin uptake to cells within the local injection area.
Nuclear Medicine Imaging and Cardiotoxicity
2017, Anticancer Treatments and Cardiotoxicity: Mechanisms, Diagnostic and Therapeutic InterventionsNoninvasive imaging of cardiovascular injury related to the treatment of cancer
2014, JACC: Cardiovascular ImagingCitation Excerpt :Investigators developed monoclonal antibodies, 111In and 99mTc, to identify these heavy chains and thereby assess the degree of myocyte damage in response to inflammation. Studies by Valdes Olmos et al. (101) and Maini et al. (102) both show positive correlation between the cumulative dose of anthracycline and the uptake of antimyosin in the myocardium, with later deterioration of LVEF (101,102) (Fig. 3). Importantly, however, the specificity of 111In-antimyosin scintigraphy is low (25% to 50%) for predicting decrements in LVEF 12 months after receipt of cancer treatment (78).
Doxorubicin augments rAAV-2 transduction in rat neuronal cells
2009, Neurochemistry InternationalAnthracycline-induced cardiomyopathy
2009, Presse MedicaleMonitoring chemotherapy-induced cardiotoxicity: Role of cardiac nuclear imaging
2006, Journal of Nuclear Cardiology